Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient is male or female 18 to 65 years of age, inclusive.~* The patient has a diagnosis of primary FM as defined by the 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria (American College of Rheumatology Preliminary Diagnostic Criteria)~* The in-clinic 7-day recall NRS average daily pain intensity score at Screening Visit within protocol specified range.~Exclusion Criteria:~* History of or evidence for a diagnosis of borderline personality disorder (BPD).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TNX-102 SL Tablets, 5.6 mg (Type: EXPERIMENTAL): 1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
- Placebo SL Tablet (Type: PLACEBO_COMPARATOR): 1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).